Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENFORCE PLUS Janssen vaccine platelet and anti-PF4 study
2021-003188-90Phase 4Terminated
- Sponsor
- Rigshospitalet
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label trial of Ad26.COV2.S in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Change in anti-PF4 antibodies. Started Jun 2021; status: terminated.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003188-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003188-90.